Charlotte, N.C – Bourne Partners (“Bourne”), a leading financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors, announces the appointment of Matthew H. Bullard, former Managing Director at HealthCare Royalty Partners, as a Strategic Advisor to the firm. Mr. Bullard will support the continued growth of Bourne’s royalty monetization and revenue interest financing coverage by supporting deal origination, structuring, and execution.

Based in Raleigh, N.C, Mr. Bullard has over 20 years of experience as a healthcare investor with a track record of over $5 billion of specialized financings. Most recently, Mr. Bullard was a Managing Director at HealthCare Royalty Partners where he was responsible for identifying, structuring, and negotiating investments across royalty monetization, revenue interest financing, and debt strategies. Mr. Bullard was previously a Partner at NovaQuest Capital Management, a leading life sciences and healthcare investor, where he focused on product-based investments in late-stage clinical and commercial biopharma programs. Matt holds a BS in accounting from University of North Carolina at Greensboro and an MBA from University of North Carolina at Chapel Hill.

“We are excited to welcome Matt into our organization at a time when demand for non-dilutive funding and specialized financings is at a record high”, said Jeremy Johnson, Senior Managing Director and Head of Investment Banking at Bourne Partners. “Our biopharma clients are demanding high quality advisory services as they navigate through pivotal phases of their company’s growth amid challenging macroeconomic conditions. Matt’s deep experience in structuring royalty monetization and revenue interest financing deals will add significant value to our biopharma service offering, and strengthen Bourne’s positioning as the leading biopharma-focused M&A advisor”.

“Bourne has an outstanding reputation in biopharma M&A advisory, and I am pleased to come onboard in a Strategic Advisor capacity and support the continued expansion of its royalty monetization and revenue interest financing coverage,” said Mr. Bullard. “With a team of highly respected industry professionals and a 20+ year track record in biopharma M&A advisory, Bourne is positioned to support innovative biopharma companies through complex financings, and help inventors maximize value from their royalty streams to fund the next wave of innovation in our industry.”

About Bourne Partners

Bourne Partners is a financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors. Located in Charlotte, North Carolina, the company offers investment banking and transaction advisory services. As owners and operators with over 20 years of experience, Bourne Partners strives to enrich the lives and improve the health and well-being of their partners and patients by facilitating the efficient movement of capital through the global healthcare sector. For more information, please visit here.